Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3- nitropropionic acid

Neurobiology of Disease

Volumn 6, Issue 4, 1999, Pages 259-268

  Dautry, Caroline ^a   Condé, Francoise ^a   Brouillet, Emmanuel ^a   Mittoux, Vincent ^a   Beal, M Flint ^b   Bloch, Gilles ^a   Hantraye, Philippe ^a  

^a DIF   (France)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

3 nitropropionic acid; Baboon; Choline; Huntington's disease; Lactate; N acetylaspartate; Neurodegeneration; Phosphocreatine creatine; Quantitative 1H MRS

Indexed keywords

3 NITROPROPIONIC ACID; CHOLINE; CREATINE PHOSPHATE; ENZYME INHIBITOR; LACTIC ACID; N ACETYLASPARTIC ACID; SUCCINATE DEHYDROGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; BRAIN MITOCHONDRION; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME INHIBITION; HUNTINGTON CHOREA; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 0032888009     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1999.0244     Document Type: Article

References (44)

1. Albin R. L., Greenamyre J. T. Alternative excitotoxic hypotheses. Neurology. 42:1992;733-738.
2. Bachoud-Levi A. C., Hantraye P., Peschanski M. Prospectives for cell and gene therapy in Huntington's disease. Prog. Brain Res. 117:1998;507-520.
3. Barker P. B., Soher B. J., Blackband S. J., Chatman J. C., Mathews V. P., Bryan R. N. Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference. NMR Biomed. 6:1993;89-94.
4. Bates T. E., Strangward J. K., Davey G. P., Munro P. M. G., Clark J. B. Inhibition of N-acetylaspartate production: Implications for 1H MRS studies in vivo. NeuroReport. 7:1996;1397-1400.
5. Bazzett T. J., Becker J. B., Kaatz K. W., Albin R. L. Chronic intraastriatal dialytic administration of quinolinic acid produces selective neural degeneration. Exp. Neurol. 120:1993;117-185.
6. Bazzett T. J., Falik R. C., Becker J. B., Albin R. L. Chronic administration of malonic acid produces selective neural degeneration and transient changes in calbindin immunoreactivity in rat striatum. Exp. Neurol. 134:1995;244-252.
7. Birken D. L., Oldendorf W. H. N-acetyl-l-aspartic acid: A literature review of a compound prominent in 1H NMR spectroscopic studies of brain. Neurosci. Biobehav. Rev. 13:1989;23-31.
8. Brouillet E., Guyot M. C., Mittoux V., Altairac S., Conde F., Palfi S., Hantraye P. Partial inhibition of brain succinate deshydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70:1998;794-805.
9. Brouillet E., Hantraye P., Ferrante R. J., Dolan R., L-W A., Kowall N. W., Beal M. F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. USA. 92:1995a;7105-7109.
10. Brouillet E., Hantraye P. Effects of chronic intoxication with MPTP and 3-nitropropionic acid in primates. Curr. Opin. Neurol. 8:1995;469-473.
11. Brouillet E., Palfi S., Ferrante R. J., Leroy-Willig A., Guyot M. C., Beal M. F., Hantraye P. Systemic administration of 3-nitropropionic acid in primates: correlation between MRI findings and symptomatology (Abstract No. 21:490). Society for Neuroscience. 1995b.
12. Burri R., Steffen C., Herschkowitz N. N-acetyl-l-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development. Dev. Neurosci. 13:1991;403-411.
13. Christiansen P., Henriksen O., Stubgaard M., Gideon P., Larsson H. B. W. In vivo quantification of brain metabolites by 1H-MRS using water as in internal standard. Magn. Reson. Imaging. 11:1993;107-118.
14. D'Adamo A. F. Jr., Yatsu F. M. Acetate metabolism in the nervous system. N-acetyl-l-aspartic acid and the biosynthesis of brain lipids. J. Neurochem. 13:1966;961-965.
15. ième Colloque de la Société des Neurosciences.
16. Davie C. A., Barker G. J., Quinn N., Tofts P. S., Miller D. H. Proton MRS in Huntington's disease. Lancet. 343:1994;1580.
17. De Stefano N., Matthews P. M., Arnold D. L. Reversible decreases in N-acetylaspartate after acute brain injury. Magn. Reson. Med. 34:1995;721-727.
18. Ebisu T., Rooney W. D., Graham S. H., Weiner M. W., Maudsley A. A. N-acetylaspartate as an in vivo marker of neuronal viability in kainate-induced status epilepticus: 1H magnetic resonance spectroscopic imaging. J. Cereb. Blood Flow Metab. 14:1994;373-382.
19. Ernst T., Kreis R., Ross B. D. Absolute quantitation of water and metabolites in the human brain. I. Compartments and water. J. Magn. Reson. B. 102:1993;1-8.
20. Frahm J., Michaelis T., Merboldt K. D., Hanicke W., Gyngell M. L., Bruhn H. On the N-acetyl methyl resonance in localised 1H NMR spectra of human brain. NMR Biomed. 4:1991;201-204.
21. Harms L., Meierkord H., Timm G., Pfeiffer L., Ludolph A. C. Decreased N-acetylaspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: A proton magnetic resonance spectroscopy study. Neurol. Neurosurg. Psychiat. 62:1997;27-30.
22. Hassel B., Sonnewald U. Selective inhibition of the tricarboxilic acid cycle of GABAergic neurons with 3-nitropropionic acid in vivo. J. Neurochem. 65:1995;1184-1191.
23. Henriksen O. In vivo quantitation of metabolite concentrations in the brain by means of proton MRS. NMR Biomed. 8:1995;139-148.
24. Holshouser B. A., Komu M., Moller H. E., Zijlmans J., Kolem H., Hinshaw D. B. Jr., Sonninen P., Vermathen P., Heerschap A., Masur H., Rinne U. K., de Koster A., Tosk J. M. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: A multicenter pilot study. Magn. Reson. Med. 33:1995;589-594.
25. Jenkins B. G., Koroshetz W. J., Beal M. F., Rosen B. R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 43:1993;2689-2695.
26. Jenkins B. G., Rosa H. D., Chen Y. C. I., Makabe T., Myers R., MacDonald M., Rosen B. R., Beal M. F., Koroshetz W. J. 1H NMR spectroscopy studies of Huntington's disease. Correlations with CAG repeat numbers. Neurology. 50:1998;1357-1365.
27. Johns D. R. Mitochondrial DNA and disease. N. Engl. J. Med. 333:1995;638-644.
28. Koroshetz W. J., Jenkins B. G., Rosen B. R., Beal M. F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41:1997;160-165.
29. Kreis R., Ernst T., Ross B. D. Absolute quantitation of water and metabolites in the human brain. II Metabolite concentrations. J. Magn. Reson. B. 102:1993;1-8.
30. Kuhmonen J., Sivenius J., Riekkinen P. J. Sr., Kauppinen R. A. Decrease in brain choline-containing compounds following a short period of global ischemia in gerbils as detected by 1H NMR spectroscopy in vivo. NMR Biomed. 7:1994;231-236.
31. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper C., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S., Bates G. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
32. Michaelis T., Merboldt K.-D., Bruhn H., Hanicke W., Frahm J. Absolute concentrations of metabolites in the adult human in vivo: Quantification of localized proton MR spectra. Radiology. 187:1993;219-227.
33. Miller B. L. A review of chemical issues in 1H NMR spectroscopy: N-acetylaspartate, creatine and choline. NMR Biomed. 4:1991;47-52.
34. Moats R. A., Ernst T., Shonk T. K., Ross B. D. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn. Reson. Med. 32:1994;110-115.
35. Palfi S., Condé F., Riche D., Brouillet E., Dautry C., Mittoux V., Chibois A., Peschanski M., Hantraye P. Fetal striatal allografts reverse cognition deficits in a primate model of Huntington disease. Nature Med. 4:1998;963-966.
36. Palfi S., Ferrante R. J., Brouillet E., Beal M. F., Dolan R., Guyot M. C., Peschanski M., Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's Disease. J. Neurosci. 16:1996;3019-3025.
37. Tallan H. H. Studies on the distribution of N-acetyl-l-aspartic acid in brain. J. Biol. Chem. 224:1956;41-45.
38. Taylor-Robinson S. D., Weeks R. A., Bryant D. J., Sargentoni J., Marcus C. D., Harding A. E., Brokks D. J. Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxicity theory. Movement Disorders. 11:1996;167-173.
39. Taylor-Robinson S. D., Weeks R. A., Sargentoni J., Marcus C. D., Bryant D. J., Harding A. E., Brooks D. J. Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet. 343:1994;1170.
40. Truckenmiller M. E., Namboodiri M. A. A., Brownstein M. J., Neale J. H. N-acetylation of l-aspartate in the nervous system: Differential distribution of a specific enzyme. J. Neurochem. 45:1985;1658-1662.
41. Urenjak J., Williams S. R., Gadian D. G., Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 59:1992;55-61.
42. Van Der Toorn A., Dijkhuizen R. M., Tulleken C. A. F., Nicolay K. T1 and T2 relaxation times of the major 1H-containing metabolites in rat brain after focal ischemia. NMR Biomed. 8:1995;245-252.
43. Vion-Dury J., Nicoli F., Salvan A., Confort-Gouny S., Dhiver C., Cozzone P. J. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet. 345:1994;60-61.
44. Wallace D. C. Mitochondrial genetics: A paradigm for aging and degenerative diseases. Science. 256:1992;628-632.